SlimShape Device for Abdominal Fat and Circumference Reduction

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-13

Study Completion Date

2018-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, one-arm, baseline-controlled, clinical study for the evaluation of the SlimShape device for non-invasive abdominal fat and circumference reduction.

Study subjects will undergo SlimShape treatments on the abdominal area.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction

NCT02700152

Excess Abdominal Fat

UNKNOWN NA

CoolSculpting in the Abdomen Using Applicator With and Without CCI

NCT02787850

Body Fat Disorder

COMPLETED NA

UltraShape Device for Thigh Fat and Circumference Reduction vs. Control

NCT02488083

Unwanted Thigh Fat

UNKNOWN NA

Study of Weight Loss Using Gastric Stimulation in Obese Patients

NCT00200083

Obesity Morbid Obesity

COMPLETED NA

UltraShape Power for Abdominal Fat and Circumference Reduction

NCT02748928

Excess Abdominal Fat

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this trial is to evaluate the safety and efficacy of the SlimShape device utilizing the SlimShape Applicator Belt for abdominal non-invasive fat and circumference reduction. Eligible subjects will receive up to 3 bi-weekly treatments (2 weeks interval) with the SlimShape device utilizing the SlimShape Applicator Belt according to the study protocol.

The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment.

Each subject will be enrolled for total expected study duration of up to 16 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fat Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abdominal fat reduction treatment

SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.

Group Type EXPERIMENTAL

SlimShape

Intervention Type DEVICE

SlimShape radiofrequency treatment to the abdomen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SlimShape

SlimShape radiofrequency treatment to the abdomen

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent to participate in the study.
2. Female and male subjects, ≥18 and ≤60 years of age at the time of enrollment
3. Fitzpatrick Skin Type I to VI
4. BMI interval: 18.5 ≤ BMI ≤ 30 (normal to overweight, but not obese).
5. If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
6. In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
7. General good health confirmed by medical history and skin examination of the treated area.
8. Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
9. Willing to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
10. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.

Exclusion Criteria

1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism
2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
3. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions
4. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
5. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone
6. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction
7. Previous body contouring procedures in the treatment area within 12 months
8. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
9. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity)
10. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
11. Allergy to any component of the lotion (VelaSpray Ease) used in this study
12. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
13. Very poor skin quality (i.e., severe laxity)
14. Abdominal wall diastasis or hernia on physical examination
15. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
16. Obesity (BMI \> 30)
17. Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study
18. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months)
19. Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration).
20. Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s).
21. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes